News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Swiss Approve Novartis International AG Drug For Blindness
August 29, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Europe
MORE ON THIS TOPIC
Approvals
AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer
May 28, 2026
·
1 min read
·
Tristan Manalac
Insights
France’s biotech ecosystem: science, capital and scale
May 28, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Rare diseases
FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug
May 27, 2026
·
3 min read
·
Heather McKenzie
Vaccines
Lilly just bought renowned regulator Peter Marks a pipeline to play with
May 27, 2026
·
2 min read
·
Annalee Armstrong